ImmuPharma (LON:IMM) Shares Up 26.5% - Time to Buy?

Key Points

• ImmuPharma's shares surged 26.5% on Monday, reaching a peak price of GBX 19.35 ($0.26) before closing at GBX 17.68 ($0.24).
• The company reported a net margin of 3,519.56% but has a significantly negative PE ratio of -2,044.94 and a projected earnings per share of -339.00 for the current year.
• ImmuPharma is focused on developing peptide-based therapeutics for autoimmune diseases and anti-infectives, with its lead program, Lupuzor™, being evaluated for the treatment of Lupus.

ImmuPharma plc (LON:IMM - Get Free Report) shot up 26.5% on Monday . The company traded as high as GBX 19.35 ($0.26) and last traded at GBX 17.68 ($0.24). 37,012,531 shares traded hands during trading, an increase of 347% from the average session volume of 8,286,141 shares. The stock had previously closed at GBX 13.98 ($0.19).

ImmuPharma Stock Up 30.2%

The stock has a 50-day simple moving average of GBX 3.12 and a two-hundred day simple moving average of GBX 2.91. The firm has a market cap of £90.95 million, a PE ratio of -2,044.94 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Research analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.